Tom Mihaljevic, MD, is CEO and President of Cleveland Clinic, one of America’s top hospitals (U.S. News & World Report). He has served in this role since January 2018.
Dr. Mihaljevic leads a $12.4 billion globally integrated healthcare system with a main campus, 22 hospitals, and 226 outpatient locations, including facilities in Florida, Nevada, Toronto, Abu Dhabi and London. Cleveland Clinic has 72,500 caregivers worldwide, including 5,050 physicians and scientists.
Under Dr. Mihaljevic’s leadership, Cleveland Clinic’s mission is caring for life, researching for health and educating those who serve.
His vision is to make Cleveland Clinic the best place for care anywhere and the best place to work in healthcare.
Dr. Mihaljevic’s guiding principles are to treat patients and caregivers like family. He strives to care for each community served, and to grow Cleveland Clinic to serve as many people as possible.
From 2015 to 2017, Dr. Mihaljevic was CEO of Cleveland Clinic Abu Dhabi (CCAD), the first U.S. multispecialty hospital to be replicated outside of North America. He oversaw the facility’s opening and established its reputation for clinical excellence, patient experience, research, and education.
In 2011 Dr. Mihaljevic was appointed Chief of Staff and Chair of the Heart & Vascular Institute at CCAD. He led recruitment, hiring and training of the new hospital’s workforce.
Dr. Mihaljevic came to Cleveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery. He was previously on staff at Boston’s Brigham and Women’s Hospital, with an academic appointment at Harvard Medical School.
Dr. Mihaljevic is a member of the GE Board of Directors, co-chairman of the Board of Directors of the US-UAE Business Council, a member of the East Coast Executive Summit, and a director on the boards of OneTen, the Greater Cleveland Partnership, and the United Way of Greater Cleveland. He also serves on the Board of Trustees of the Musical Arts Association, the nonprofit that oversees The Cleveland Orchestra.
A native of Croatia and a U.S. citizen, Dr. Mihaljevic speaks English, German and Croatian.
As a technology and business leader, Dr. Gil is responsible for IBM Research, one of the world’s largest and most influential corporate research labs, with over 3,000 researchers. He is the 12th Director in its 76-year history. Dr. Gil leads the technology roadmap and the technical community of IBM, directing innovation strategies in areas including hybrid cloud, AI, quantum computing, and exploratory science. He is also responsible for IBM's intellectual property strategy and business.
Dr. Gil is a globally recognized leader of the quantum computing industry. Under his leadership, IBM was the first company in the world to build programmable quantum computers and make them universally available through the cloud.
An advocate of collaborative research models, Dr. Gil co-chairs the MIT-IBM Watson AI Lab, which advances fundamental AI research to the broad benefit of industry and society. He also co-chairs the COVID-19 High-Performance Computing Consortium, which provides access to the world’s most powerful high-performance computing resources in support of COVID-19 research.
Arvind Krishna is the Chairman and Chief Executive Officer of IBM. As a business leader and technologist, he has led the building and expansion of new markets for IBM in artificial intelligence, cloud, quantum computing, and blockchain. He has also played a significant role in the development of innovative IBM products and solutions based on these emerging technologies.
Over his 30-year career at IBM, Arvind led a series of bold transformations and delivered proven business results. He most recently drove the successful $34 billion acquisition of Red Hat – the largest software acquisition – that has defined the hybrid cloud market. Together, IBM and Red Hat give clients the unique ability to build mission-critical applications once and run them anywhere.
Arvind previously was senior vice president of Cloud and Cognitive Software, where he pioneered the company’s hybrid cloud business, transformed IBM’s entire software and services portfolio and offerings for cloud, and grew the business. He also headed IBM Research, where he drove innovation in core and emerging technologies including artificial intelligence, quantum computing, blockchain, cloud platform services, data-driven solutions, and nanotechnology. In 2016, Wired Magazine selected Arvind as “one of 25 geniuses who are creating the future of business” for his foundational work on blockchain.
Serpil Erzurum is Cleveland Clinic’s Chief Research and Academic Officer and Chair of the Lerner Research Institute. Dr. Erzurum focuses on strategic growth of enterprise-wide medical and scientific education programs; clinical, basic and translational research; and technology development to deliver the most innovative care to patients. A practicing pulmonologist and active scientist, Dr. Erzurum is also a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Her scientific contributions and leadership in pulmonary research have led to diagnostic and therapeutic advances in lung diseases and helped to identify human physiologic adaptive responses to high-altitude hypoxia.
Dr. Erzurum graduated from Northeast Ohio Medical University. She completed her residency in internal medicine at Baylor College of Medicine, a fellowship at the University of Colorado Health Sciences Center and postdoctoral training at the National Heart, Lung and Blood Institute in Bethesda, Maryland.
Dr. Erzurum has won numerous awards, including the prestigious MERIT award from the National Heart, Lung and Blood Institute, the American Medical Women’s Association Award for Excellence and the Elizabeth Rich Award from the American Thoracic Society in recognition of her efforts mentoring women. Dr. Erzurum is the recipient of the 2022 Alfred and Normal Lerner Humanitarian Award, which is Cleveland Clinic’s most prestigious physician honor. It celebrates physicians whose selfless dedication, boundless compassion and tireless work have made the most profound and singular contribution to the good of humankind. She is a member of the National Academy of Medicine, the American Society for Clinical Investigation and the Association of American Physicians. Dr. Erzurum has published more than 300 articles and is among the top 1% cited researchers in the world.
Will Rowberry is responsible for the development and delivery of the Cleveland Clinic London commercial strategy including business development, marketing, communications and payor relationships.
Will has extensive experience working across the healthcare industry in both the private and public sectors. Prior to joining Cleveland Clinic London, he was a Director in the Healthcare and Life Sciences team at the Brunswick Group, was formerly Head of Corporate Finance at Circle Health and is a Fellow of the Institute of Chartered Accountants in England and Wales.
Chief Research Information Officer and Executive Program lead for the Discovery Accelerator
Cleveland Clinic
Dr. Jehi is professor of neurology at Cleveland Clinic Lerner College of Medicine, and an epilepsy specialist at Cleveland Clinic since 2006. She is Director of the Outcomes Research program for epilepsy, the Chief Research Information Officer for the Cleveland Clinic Health System, and the Executive Program lead for the Discovery Accelerator focused on artificial intelligence, quantum computing, and data science education.
She is currently spearheading multi-institutional National Institutes of Health-funded grants focused on data science. She has led teams that developed the first nomograms for individualized outcome prediction after epilepsy surgery, and advanced mechanistic understanding of outcomes. Her work was featured by Lancet Neurology in the Top 5 Innovations of 2015, and in the 'Notables in Healthcare" Award by Crain's Business in 2021. Her data-driven algorithms for clinical care decision-making are being used, studied and expanded worldwide. Dr. Jehi holds several research leadership roles at Cleveland Clinic. As co-director of Network Capacity for the Clinical and Translational Science Collaborative of Cleveland, her team facilitates multi-center clinical trials through streamlined recruitment efforts, using the electronic health record. She is the principal investigator of Cleveland Clinic’s Biorepository, a role leveraging information technology, enterprise analytics and regulatory support to efficiently scale up and incorporate biobanking efforts within clinical workflow. She is a vice-chair of Cleveland Clinic’s Institutional Review Board.
She chairs several key commissions in the International League Against Epilepsy and the American Epilepsy Society. She has more than 170 peer-reviewed publications, 12 book chapters and is a regular reviewer for NIH study sections, and an invited speaker to international meetings on the topics of epilepsy surgery, outcome prediction, and data science.
Dr. Jehi received her medical degree from American University of Beirut. She completed her residency in neurology and fellowship in clinical neurophysiology at Cleveland Clinic, and holds a Master’s degree in Health Care Delivery Science from Dartmouth College.
Tommaso Falcone, MD is Chief of Staff, Chief Academic Officer and Medical Director of Cleveland Clinic London. He has over 20 years’ experience with Cleveland Clinic, most recently as Professor of Obstetrics, Gynecology and Reproductive Biology at the Cleveland Clinic Lerner College of Medicine.
Dr. Falcone is certified by the American Board of Obstetrics and Gynecology in general obstetrics and gynecology and reproductive endocrinology and infertility, and by the Royal College of Physicians and Surgeons of Canada. He is also a Fellow of the Royal College of Obstetricians and Gynaecologists of England ad eundem. Dr. Falcone was the senior author on the first publication in the world on gynecologic robot surgery and a member of the team that performed the first uterus transplant in the US.
